Government-Owned Inventions; Availability for Licensing, 48216-48218 [E8-18983]
Download as PDF
<![CDATA[
48216
Federal Register / Vol. 73, No. 160 / Monday, August 18, 2008 / Notices
sroberts on PROD1PC70 with NOTICES
2. YW Lin et al., NUP98-HOXD13
transgenic mice develop a highly
penetrant, severe myelodysplastic
syndrome that progresses to acute
leukemia. Blood. 2005 Jul 1;106(1):287–
295.
Patent Status: HHS Reference No. E–
071–2007/0—Research Tool.
Licensing Status: Available for nonexclusive licensing.
Licensing Contact: Jennifer Wong;
301–435–4633; wongje@mail.nih.gov.
Collaborative Research Opportunity:
The Leukemia Biology Section, Genetics
Branch, National Cancer Institute is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize the
NHD13 mouse model. Please contact
John D. Hewes, Ph.D. at 301–435–3121
or hewesj@mail.nih.gov for more
information.
Conjugates of Ligand, Linker, and
Cytotoxic Agent and Related
Compositions and Methods of Use
Description of Technology: Systemic
toxicity of drugs is one of the most
serious problems in cancer
chemotherapy and frequently is dose
limiting. Specific delivery of cytotoxic
drugs to cancer cells remains among the
most intractable problems of cancer
therapy. Targeted delivery of antiproliferation drugs through the cell
surface receptors that are over expressed
on cancer cells can reduce systemic
toxicity and increase effectiveness of a
treatment.
The present invention describes
cytotoxic compounds with an
intracellular target that can selectively
enter tumor cells through specific
receptors on the cell surface. The
invention also describes a conjugate
comprising a cytotoxic agent, a linker
arm and a ligand capable of delivering
a cytotoxic agent in a cell specific
manner. Such conjugates of a cytotoxic
agent and a ligand (delivery moiety)
have increased selectivity for tumor
cells. The toxic moiety and the ligand
are joined by a linker arm that is stable
in circulation, but is easily cleaved in
lysosomes upon internalization of the
conjugate. A panel of compounds
comprised of a variety of cytotoxic
warheads, against various intracellular
targets linked to an assortment of
ligands, has been developed and tested
in a model system. Ligand moieties of
these conjugates are capable of specific
delivery of cytotoxic agents to receptors
that are frequently over expressed in
gastric, colon, lung, breast, ovarian and
pancreatic tumors. These compounds
have the potential to be highly effective
anti-tumor agents with considerably
VerDate Aug<31>2005
16:50 Aug 15, 2008
Jkt 214001
little negative effect. This disclosed
technology could provide new and
exciting methodologies to treat cancer.
Applications: Anti-tumor agent for
gastric, colon, lung, breast, ovarian and
pancreatic tumors.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Inventors: Nadya I. Tarasova et al.
(NCI).
Patent Status: U.S. Patent Application
No. 10/505,239 filed 19 Aug 2004,
claiming priority to 27 Feb 2002 (HHS
Reference No. E–057–2002/2-US–02).
Licensing Contact: Adaku
Nwachukwu, J.D.; 301/435–5560;
madua@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute Structural
Biophysics Laboratory is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize Conjugates of Ligand,
Linker, and Cytotoxic Agent and Related
Compositions and Methods of Use.
Please contact John D. Hewes, Ph.D. at
301–435–3121 or hewesj@mail.nih.gov
for more information.
SH2 Domain Binding Inhibitors
Description of Technology: Signal
transduction processes underlie the
transfer of extracellular information to
the interior of the cell and ultimately to
the nucleus. A variety of signal
transduction processes are critical for
normal cellular homeostasis, with
protein-tyrosine kinases (PTKs) playing
central roles in many of these pathways.
Examples of such PTKs include the
PDGF receptor, the FGF receptor, the
HGF receptor, members of the EGF
receptor family, such as the EGF
receptor, erb-B2, erb-B3 and erb-B4, the
src kinase family, Fak kinase and the Jak
kinase family. Protein-tyrosine
phosphorylation that results from the
action of PTKs can modulate the activity
of certain target enzymes as well as
facilitate the formation of specific multiprotein signaling complexes through the
actions of homologous protein modules
termed Src homology 2 (SH2) domains,
which recognize specific
phosphotyrosyl containing sequences. A
malfunction in this system through
tyrosine kinase overexpression and/or
deregulation can be manifested by
various oncogenic and
hyperproliferative disorders, including
cancers, inflammation, autoimmune
disease, hyperproliferative skin
disorders, psoriasis and allergy/asthma,
etc. The disclosed compounds, e.g.
peptides, preferably, macrocyclic
peptides, are Grb2 SH2 domain
signaling antagonists with enhanced
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
binding affinity. The claims of the
current application are directed to
compositions of matter and methods of
use which provide for the diagnosis,
testing and treatment of the
aforementioned disease states.
Applications: For treatment of cancer,
inflammation, autoimmune diseases,
hyperproliferative skin disorders,
psoriasis and asthma.
Development Status: The technology
is currently in an early pre-clinical stage
of development.
Inventors: Terrence R. Burke, Jr., et al.
(NCI).
Patent Status:
• U.S. Patent No. 6,977,241 issued 20
Dec 2005 (HHS Reference No. E–262–
2000/0–US–03).
• U.S. Patent Application No. 10/
517,717 filed 17 Mar 2005, allowed
(HHS Reference No. E–262–2000/1-US–
03).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Adaku
Nwachukwu, J.D.; 301–435–5560;
madua@mail.nih.gov.
Dated: August 7, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E8–18982 Filed 8–19–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
E:\FR\FM\18AUN1.SGM
18AUN1
Federal Register / Vol. 73, No. 160 / Monday, August 18, 2008 / Notices
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
sroberts on PROD1PC70 with NOTICES
Broadly Neutralizing Anti-HIV
Monoclonal Antibody That Targets a
New Epitope on gp41
Description of Technology: Blocking
entry of HIV into cells and vaccine
development against HIV are the prime
targets of HIV therapy and prevention,
respectively. Current invention
describes a monoclonal Fab anti-HIV
antibody isolated through panning
against the chimeric construct NCCGgp41 by Antibodies-by-Design
(Morphosys). One of the antibodies has
broadly neutralization ability against
several HIV subtypes in an envelopepseudotyped-virus neutralization assay.
This antibody was also shown to have
synergistic effect with a gp41-derived
peptide discovered in this laboratory in
inhibiting HIV–1 fusion.
Applications: Research tool or
screening for HIV vaccine.
Advantages: Can be potentially used
as a therapeutic agent to block HIV–1
entry into cells.
Development Status: In vitro data
available.
Market: For the development of drugs
against HIV.
Inventors: G. Marius Clore et al.
(NIDDK).
Publications:
1. E Gustchina et al. A monoclonal
Fab derived from a human nonimmune
phage library reveals a new epitope on
gp41 and neutralizes diverse human
immunodeficiency virus type 1 strains.
J Virol. 2007 Dec;81(23):12946–12953.
2. E Gustchina et al. Sequestering the
pre-hairpin intermediate of gp41 by
peptide N36Mut(e,g) potentiates the
human immunodeficiency virus type 1
neutralizing activity of monoclonal
antibodies against the N-terminal helical
repeat of gp41. J. Virol. in press (2008).
Patent Status: HHS Reference No. E–
229–2008/0—Research Tool. Patent
protection is not being pursued for this
technology.
Licensing Status: This invention is
available for non-exclusive licensing as
a research tool.
Licensing Contact: Sally Hu, Ph.D.;
301–435–5606; HuS@mail.nih.gov.
Collaborative Research Opportunity:
The NIH, Laboratory of Chemical
Physics is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this monoclonal Fab.
Please contact Dr. G.M. Clore at 301–496
0782 and/or e-mail at
VerDate Aug<31>2005
16:50 Aug 15, 2008
Jkt 214001
mariusc@mail.nih.gov for more
information.
Polyamine Compounds That Bind Tar
RNA of HIV and Methods of Treating
Viral Disorders
Description of Technology: Current
HIV treatment involves applying
cocktail of drugs targeting either virus
entry or one of three viral enzymes.
Because patients eventually develop
resistance to the cocktail, a new class of
drugs is urgently needed. Current
invention describes a new class of
polyamine compounds that specifically
bind to HIV RNA at micromolar range
to prevent binding of viral RNA to viral
proteins and therefore blocking viral
replication. This differs with the
mechanisms of current HIV drugs in the
market and therefore offers new strategy
in HIV treatment and prevention.
Furthermore, this class of compound
may aid future development of drugs
targeting RNA.
Applications: Treatment and
prevention of HIV infection.
Advantages: Novel strategy for HIV
treatment and prevention; Specific
binding to HIV RNA and strong activity.
Development Status: In vitro data
available.
Market: HIV therapeutics and
preventatives.
Inventors: Daniel Appella et al.
(NIDDK).
Publications: Manuscripts in
preparation.
Patent Status: U.S. Provisional
Application No. 61/123,076 filed 04 Apr
2008 (HHS Reference No. E–159–2008/
0-US–01).
Licensing Status: This invention is
available for exclusive or non-exclusive
licensing.
Licensing Contact: Sally Hu, Ph.D.;
301–435–5606; HuS@mail.nih.gov.
Collaborative Research Opportunity:
The NIDDK, Laboratory of Bioorganic
Chemistry, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize the application of TARbinding polyamines for the treatment of
HIV infections. Please contact Daniel
Appella at 301–451–1052 or
appellad@niddk.nih.gov for more
information.
Monoclonal Antibodies to HIV–1 Vpr
Description of Technology: Available
for licensing are monoclonal antibodies
against HIV–1 viral protein R (Vpr) and
the respective hybridoma cell lines
expressing the same. The antibodies
provide a means for detecting HIV–1
Vpr. Currently, the mechanism of HIV
pathogenesis believed to involve viral
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
48217
replication inside immune cells and
other cells. At present, there are no
clinical assays for detecting HIV–1 Vpr.
Vpr circulates at detectable levels in the
blood and is likely derived from
degraded virions or released from
infected cells. Vpr facilitates viral
replication and disrupt normal cell
function. Thus measurement of Vpr
levels in blood, extracellular fluid, and
tissue may be of benefit in
understanding the pathogenesis of HIV–
1 infection and its myriad
complications.
The hybridoma cell lines (9F12 and
10F2) were selected from a group of
hybridoma cell lines. These antibodies
can be used for detection, including
immunoasssays (ELISA) and
immunoaffinity-capillary
electrophoresis. The amount of detected
HIV–1 Vpr is compared to a
standardized control sample for
determining the progress of disease or
the presence of known complications
like neuropathy, dementia, metabolic
syndrome, or nephropathy.
Inventors: Jeffrey Kopp (NIDDK),
Terence Philips (NBIB), Schubert Ulrich
(NIAID), John Yewell (NIAID).
Patent Status: U.S. Patent Application
No. 11/630,880 filed 27 Jun 2005 (HHS
Reference No. E–141–2003/0–US–03).
Licensing Status: Available for
licensing.
Licensing Contact: Michael
Shmilovich, Esq.; 301–435–5019;
shmilovm@mail.nih.gov.
Anti-Pax 2 Antibody
Description of Technology: Available
for licensing and commercialization are
anti-Pax 2 polyclonal antibodies that
can be used for the detection of Pax-2
protein expression in a variety of kidney
and neuronal tissues. Pax-2 protein, a
transcription factor active during early
kidney development, is expressed at
high levels in almost all renal
proliferative diseases such as renal
cancer, polycystic kidney disease and
acute renal failure.
The Pax-2 protein has also been
linked to Wilms’ tumor, a cancerous
kidney tumor accounting for ∼6% of
childhood cancers, and for which ∼500
new cases are diagnosed each year in
the U.S. Wilms’ tumors are hard to
diagnose in the early stage because they
can grow quite large without causing
any pain. While abdominal ultrasound
may be used for detection, it is not a
practical screening test for otherwise
healthy children. There are no blood
tests or other tests for screening for
Wilms’ tumors which, if diagnosed
sufficiently early, may be treated with
surgery, chemotherapy, and/or radiation
therapy.
E:\FR\FM\18AUN1.SGM
18AUN1
48218
Federal Register / Vol. 73, No. 160 / Monday, August 18, 2008 / Notices
Potential applications of this
technology may also include detection
of Pax-2 protein in urine for both
chronic and acute renal disease.
Applications: Diagnostics for renal
diseases; Research tools for evaluating
disease processes of the kidney and
other tissues through Pax-2 protein
expression in the relevant tissues.
Development Status: Ready for
commercialization.
Patent Status: HHS Reference No. B–
039–1996/0—Research Tool. Patent
protection is not being pursued for this
technology.
Inventor: Gregory Dressler (NICHD).
Relevant Publications:
1. GR Dressler. Another niche for
Notch. Kidney Int. 2008
Jun;73(11):1207–1209.
2. SR Patel et al. The BRCT-domain
containing protein PTIP links PAX2 to
a histone H3, lysine 4 methyltransferase
complex. Dev Cell. 2007 Oct;13(4):580–
592.
3. GR Dressler. The cellular basis of
kidney development. Annu Rev Cell
Dev Biol. 2006;22:509–529.
4. GB Silberstein et al. Expression of
the PAX2 oncogene in human breast
cancer and its role in progesteronedependent mammary growth. Oncogene.
2002 Feb7;21(7):1009–1016.
5. GR Dressler and AS Woolf. Pax2 in
development and renal disease. Int J
Dev Biol. 1999;43(5):463–468 (Review).
6. GR Dressler. Pax-2, kidney
development, and oncogenesis. Med
Pediatr Oncol. 1996 Nov;27(5):440–444.
7. GR Dressler and EC Douglass. Pax2 is a DNA-binding protein expressed in
embryonic kidney and Wilms tumor.
Proc Natl Acad Sci USA. 1992 Feb
15;89(4):1179–1183.
Licensing Status: Available for nonexclusive licensing as biological
materials (internal use or commercial
use).
Licensing Contact: RC Tang, JD, LLM;
301–435–5031; tangrc@mail.nih.gov.
Dated: August 7, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E8–18983 Filed 8–19–08; 8:45 am]
BILLING CODE 4140–01–P
sroberts on PROD1PC70 with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
AGENCY:
VerDate Aug<31>2005
16:50 Aug 15, 2008
Jkt 214001
ACTION:
Notice.
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Species-Independent A3 Adenosine
Receptor Agonists
Description of Technology: The A3
adenosine receptor (A3AR) subtype has
been linked with helping protect the
heart from ischemia, controlling
inflammation, and regulating cell
proliferation. Agonists of the human
A3AR subtype have been described;
however, they lack selectivity for the
corresponding receptor of the mouse.
This poses a problem for clinical
development because animal model
testing is important for pre-clinical
validation of drug function.
Consequently, a novel agonist was made
that is selective for the mouse A3AR
while retaining selectivity for the
human receptor. This innovation should
facilitate moving A3 agonists into the
clinical phase of drug development with
confidence.
This invention claims speciesindependent agonists of A3AR,
specifically (N)-methanocarba adenine
nucleosides. In addition, it describes
pharmaceutical compositions
comprising such nucleosides, and
methods of use such as administering an
effective amount to a mammal.
Applications: cardiac arrhythmias or
ischemia; inflammation; stroke;
diabetes; asthma; cancer.
Market: Heart disease and cancer are
the leading causes of death for both
women and men in the United States
despite many advances in drug
development. Hence, there is a need for
drugs with unique mechanism of action.
It is noteworthy that the first synthetic
adenosine receptor agonist has recently
been approved for use in humans.
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
Development Status: Research
quantities of compounds have been
synthesized and tested for receptor
selectivity.
Inventors: Kenneth A. Jacobson and
Artem Melman (NIDDK).
Publication: A Melman et al. Design
of (N)-methanocarba adenosine 5′uronamides as species-independent A3
receptor-selective agonists. Bioorg Med
Chem Lett. 2008 May 1;18(9):2813–
2819.
Patent Status: U.S. Provisional
Application No. 61/040,985 filed 31 Mar
2008 (HHS Reference No. E–140–2008/
0–US–01).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Norbert Pontzer,
J.D., Ph.D.; 301–435–5502;
pontzern@mail.nih.gov.
Fluorescent Cell Lines for Detection of
DNA Damage
Description of Technology: The
Enhanced Level of Genomic instability
1 (ELG1) protein suppresses genomic
instability caused by DNA damage. Cell
lines for studying human ELG1 (hELG1)
have been established that stably
express a fusion protein combining
hELG1 and either Green Fluorescent
Protein (GFP) or Cyan Fluorescent
Protein (CFP). It has been shown that
the fluorescent hELG1 is an excellent
reporter for DNA damage within the
cell, with increased hELG1 localization
to the cell nucleus upon exposure to a
genotoxin. Therefore, these cell lines
may have utility as a screening tool to
detect genotoxic agents.
Available for licensing are the RPE
cell line (immortalized normal retinal
pigment epithelial cells) stably
expressing hELG1-CFP, and the U2OS
cell line (human osteosarcoma cells)
stably expressing hELG1-GFP.
Applications: High-sensitivity
screening tool for genotoxic agents.
Inventor: Kyungjae Myung (NHGRI).
Relevant Publication: In preparation.
Patent Status: DHHS Reference No. E–
108–2008/0—Research Tool. Patent
protection is not being pursued for this
technology.
Licensing Status: Available for nonexclusive licensing.
Licensing Contact: Tara L. Kirby,
Ph.D.; 301–435–4426;
tarak@mail.nih.gov.
Collaborative Research Opportunity:
The National Chemical Genomics
Center is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize the assay for detection of
genotoxic agents using RPE cell line
having hELG1–CFP. Please contact
E:\FR\FM\18AUN1.SGM
18AUN1
]]>Agencies
[Federal Register Volume 73, Number 160 (Monday, August 18, 2008)]
[Notices]
[Pages 48216-48218]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-18983]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/
[[Page 48217]]
496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement
will be required to receive copies of the patent applications.
Broadly Neutralizing Anti-HIV Monoclonal Antibody That Targets a New
Epitope on gp41
Description of Technology: Blocking entry of HIV into cells and
vaccine development against HIV are the prime targets of HIV therapy
and prevention, respectively. Current invention describes a monoclonal
Fab anti-HIV antibody isolated through panning against the chimeric
construct NCCG-gp41 by Antibodies-by-Design (Morphosys). One
of the antibodies has broadly neutralization ability against several
HIV subtypes in an envelope-pseudotyped-virus neutralization assay.
This antibody was also shown to have synergistic effect with a gp41-
derived peptide discovered in this laboratory in inhibiting HIV-1
fusion.
Applications: Research tool or screening for HIV vaccine.
Advantages: Can be potentially used as a therapeutic agent to block
HIV-1 entry into cells.
Development Status: In vitro data available.
Market: For the development of drugs against HIV.
Inventors: G. Marius Clore et al. (NIDDK).
Publications:
1. E Gustchina et al. A monoclonal Fab derived from a human
nonimmune phage library reveals a new epitope on gp41 and neutralizes
diverse human immunodeficiency virus type 1 strains. J Virol. 2007
Dec;81(23):12946-12953.
2. E Gustchina et al. Sequestering the pre-hairpin intermediate of
gp41 by peptide N36\Mut(e,g)\ potentiates the human immunodeficiency
virus type 1 neutralizing activity of monoclonal antibodies against the
N-terminal helical repeat of gp41. J. Virol. in press (2008).
Patent Status: HHS Reference No. E-229-2008/0--Research Tool.
Patent protection is not being pursued for this technology.
Licensing Status: This invention is available for non-exclusive
licensing as a research tool.
Licensing Contact: Sally Hu, Ph.D.; 301-435-5606; HuS@mail.nih.gov.
Collaborative Research Opportunity: The NIH, Laboratory of Chemical
Physics is seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate, or
commercialize this monoclonal Fab. Please contact Dr. G.M. Clore at
301-496 0782 and/or e-mail at mariusc@mail.nih.gov for more
information.
Polyamine Compounds That Bind Tar RNA of HIV and Methods of Treating
Viral Disorders
Description of Technology: Current HIV treatment involves applying
cocktail of drugs targeting either virus entry or one of three viral
enzymes. Because patients eventually develop resistance to the
cocktail, a new class of drugs is urgently needed. Current invention
describes a new class of polyamine compounds that specifically bind to
HIV RNA at micromolar range to prevent binding of viral RNA to viral
proteins and therefore blocking viral replication. This differs with
the mechanisms of current HIV drugs in the market and therefore offers
new strategy in HIV treatment and prevention. Furthermore, this class
of compound may aid future development of drugs targeting RNA.
Applications: Treatment and prevention of HIV infection.
Advantages: Novel strategy for HIV treatment and prevention;
Specific binding to HIV RNA and strong activity.
Development Status: In vitro data available.
Market: HIV therapeutics and preventatives.
Inventors: Daniel Appella et al. (NIDDK).
Publications: Manuscripts in preparation.
Patent Status: U.S. Provisional Application No. 61/123,076 filed 04
Apr 2008 (HHS Reference No. E-159-2008/0-US-01).
Licensing Status: This invention is available for exclusive or non-
exclusive licensing.
Licensing Contact: Sally Hu, Ph.D.; 301-435-5606; HuS@mail.nih.gov.
Collaborative Research Opportunity: The NIDDK, Laboratory of
Bioorganic Chemistry, is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate, or commercialize the application of TAR-binding polyamines
for the treatment of HIV infections. Please contact Daniel Appella at
301-451-1052 or appellad@niddk.nih.gov for more information.
Monoclonal Antibodies to HIV-1 Vpr
Description of Technology: Available for licensing are monoclonal
antibodies against HIV-1 viral protein R (Vpr) and the respective
hybridoma cell lines expressing the same. The antibodies provide a
means for detecting HIV-1 Vpr. Currently, the mechanism of HIV
pathogenesis believed to involve viral replication inside immune cells
and other cells. At present, there are no clinical assays for detecting
HIV-1 Vpr. Vpr circulates at detectable levels in the blood and is
likely derived from degraded virions or released from infected cells.
Vpr facilitates viral replication and disrupt normal cell function.
Thus measurement of Vpr levels in blood, extracellular fluid, and
tissue may be of benefit in understanding the pathogenesis of HIV-1
infection and its myriad complications.
The hybridoma cell lines (9F12 and 10F2) were selected from a group
of hybridoma cell lines. These antibodies can be used for detection,
including immunoasssays (ELISA) and immunoaffinity-capillary
electrophoresis. The amount of detected HIV-1 Vpr is compared to a
standardized control sample for determining the progress of disease or
the presence of known complications like neuropathy, dementia,
metabolic syndrome, or nephropathy.
Inventors: Jeffrey Kopp (NIDDK), Terence Philips (NBIB), Schubert
Ulrich (NIAID), John Yewell (NIAID).
Patent Status: U.S. Patent Application No. 11/630,880 filed 27 Jun
2005 (HHS Reference No. E-141-2003/0-US-03).
Licensing Status: Available for licensing.
Licensing Contact: Michael Shmilovich, Esq.; 301-435-5019;
shmilovm@mail.nih.gov.
Anti-Pax 2 Antibody
Description of Technology: Available for licensing and
commercialization are anti-Pax 2 polyclonal antibodies that can be used
for the detection of Pax-2 protein expression in a variety of kidney
and neuronal tissues. Pax-2 protein, a transcription factor active
during early kidney development, is expressed at high levels in almost
all renal proliferative diseases such as renal cancer, polycystic
kidney disease and acute renal failure.
The Pax-2 protein has also been linked to Wilms' tumor, a cancerous
kidney tumor accounting for ~6% of childhood cancers, and for which
~500 new cases are diagnosed each year in the U.S. Wilms' tumors are
hard to diagnose in the early stage because they can grow quite large
without causing any pain. While abdominal ultrasound may be used for
detection, it is not a practical screening test for otherwise healthy
children. There are no blood tests or other tests for screening for
Wilms' tumors which, if diagnosed sufficiently early, may be treated
with surgery, chemotherapy, and/or radiation therapy.
[[Page 48218]]
Potential applications of this technology may also include
detection of Pax-2 protein in urine for both chronic and acute renal
disease.
Applications: Diagnostics for renal diseases; Research tools for
evaluating disease processes of the kidney and other tissues through
Pax-2 protein expression in the relevant tissues.
Development Status: Ready for commercialization.
Patent Status: HHS Reference No. B-039-1996/0--Research Tool.
Patent protection is not being pursued for this technology.
Inventor: Gregory Dressler (NICHD).
Relevant Publications:
1. GR Dressler. Another niche for Notch. Kidney Int. 2008
Jun;73(11):1207-1209.
2. SR Patel et al. The BRCT-domain containing protein PTIP links
PAX2 to a histone H3, lysine 4 methyltransferase complex. Dev Cell.
2007 Oct;13(4):580-592.
3. GR Dressler. The cellular basis of kidney development. Annu Rev
Cell Dev Biol. 2006;22:509-529.
4. GB Silberstein et al. Expression of the PAX2 oncogene in human
breast cancer and its role in progesterone-dependent mammary growth.
Oncogene. 2002 Feb7;21(7):1009-1016.
5. GR Dressler and AS Woolf. Pax2 in development and renal disease.
Int J Dev Biol. 1999;43(5):463-468 (Review).
6. GR Dressler. Pax-2, kidney development, and oncogenesis. Med
Pediatr Oncol. 1996 Nov;27(5):440-444.
7. GR Dressler and EC Douglass. Pax-2 is a DNA-binding protein
expressed in embryonic kidney and Wilms tumor. Proc Natl Acad Sci USA.
1992 Feb 15;89(4):1179-1183.
Licensing Status: Available for non-exclusive licensing as
biological materials (internal use or commercial use).
Licensing Contact: RC Tang, JD, LLM; 301-435-5031;
tangrc@mail.nih.gov.
Dated: August 7, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E8-18983 Filed 8-19-08; 8:45 am]
BILLING CODE 4140-01-P
